Engineering CAR-T cells directly in the body
Problem: CAR-T works, but ex vivo manufacturing makes it slow, expensive, and hard to scale.
Breakthrough: This paper shows site-specific CAR knock-in directly in vivo using a dual delivery system for CRISPR cargo plus donor template.
What it unlocks: A future where engineered immune therapies are delivered as programmable in vivo medicines, not handcrafted cell products.
New paper from the teams of Jennifer A. Doudna, Aravind Asokan & Justin Eyquem points to a compelling inflection in cell therapy: what if we no longer had to manufacture CAR-T cells outside the body at all? Instead of leukapheresis, ex vivo editing, expansion, and reinfusion, the authors show that T cells can be precisely reprogrammed in vivo through site-specific genome engineering. Using a two-vector system with Cas9 ribonucleoproteins and an AAV6 donor carrying a promoterless CAR template, they insert the CAR into the TRAC locus, enabling T cell-specific, durable CAR expression while disrupting the endogenous TCR. In humanized mouse models, this produced therapeutic levels of CAR-T cells in vivo with activity across B-cell depletion, hematologic malignancy, and solid tumor settings.
Why this matters is not just technical elegance; it is the possibility of a platform reset for engineered cell therapies. Today’s CAR-T paradigm is constrained by bespoke manufacturing, variable product quality, long turnaround times, and high cost. Prior in vivo approaches have generally traded away precision, relying on transient expression or random integration. This study suggests a different path: programmable immunity generated directly in the patient, with locus-specific control. If translatable, that could collapse manufacturing complexity, broaden access, and redefine how we think about engineered immune medicines, not as custom cell products, but as in vivo biological programming events.
The wedge is broader than oncology. A system that can selectively deliver genome editing machinery to T cells and install large functional payloads at defined loci could become a generalizable chassis for immune-cell reprogramming across cancer, autoimmunity, and infectious disease. The core question now shifts from “can we make CAR-T better?” to “can we make cell therapy a delivery problem instead of a manufacturing problem?” That is the kind of transition that can open entirely new company architectures. The caveat is that this remains preclinical, and translation will depend on delivery efficiency, safety, specificity, and manufacturability in humans. But as a proof of concept, it is a strong signal that in vivo, site-specific immune engineering may be moving from ambition to platform reality.
Reference:
https://www.nature.com/articles/s41586-026-10235-x
